Abstract
Objectives The time-varying effect of COVID-19 on a population of a given country or territory can be measured by the Reproduction Number (R) and the Case Fatality Rate (CFR). In our study, we explore the dynamics of these two measures to test whether the virus has reached its equilibrium point and to identify the main factors explaining the current R and CFR variability across countries.
Design A retrospective study of publicly available country-level data.
Setting Fifty countries having the highest number of confirmed COVID–19 cases at the end of September 2021.
Participants Aggregated data including 213 976 306 COVID-19 cases confirmed in the selected fifty countries from the start of the epidemic to September 30, 2021.
Primary and secondary outcome measures The daily values of COVID-19 R and CFR measures were estimated using country-level data from the Our World in Data website.
Results The mean values of country–level moving averages of R and CFR went down from 1.118 and 6.3%, respectively, on June 30, 2020 to 1.083 and 3.6% on September 30, 2020 and to 1.015 and 1.8% by September 30, 2021. In parallel, the 10% to 90% inter-percentile range of R and CFR moving averages decreased from 0.288 and 13.3%, respectively, on June 30, 2020, to 0.151 and 7.7% on September 30, 2020, and to 0.107 and 3.3% by September 30, 2021. According to a comparison of the country–level 180–day moving averages of R and CFR calculated on September 30, 2021, an increase of 1% in the Delta variant share is associated with an increase of 0.0009 (95% CI 0.000 to 0.002) in the average Reproduction Number R, while an increase of 1% in the total percentage of confirmed COVID-19 cases per country’s population is associated with a decrease of 0.005 (95% CI 0.000 to 0.010) in the average R. Also, an increase of 1% in the total percentage of fully vaccinated people per country’s population is associated with a decrease of 0.04% (95% CI 0.01% to 0.06%) in the average CFR. Other virological, demographic, economic, immunization, or stringency factors were not statistically significantly associated with either R or CFR across the explored countries.
Conclusions The slow decrease in the country-level moving averages of R, approaching the level of 1.0 and accompanied by repeated outbreaks (“waves”) in various countries, may indicate that COVID-19 has reached its point of a stable endemic equilibrium. A regression analysis implies that only a prohibitively high level of herd immunity (about 63%) may stop the endemic by reaching a stable disease-free equilibrium. It also appears that fully vaccinating about 70% of a country’s population should be sufficient for bringing the CFR close to the level of a seasonal flu (about 0.1%). Thus, while the currently available vaccines prove to be effective in reducing the mortality from the existing COVID-19 variants, they are unlikely to stop the spread of the virus in the foreseeable future. It is noteworthy that no statistically significant effects of government measures restricting the people’s behavior (such as lockdowns) were found in the analyzed data.
Strengths and limitations of this study
In this study, we have explored the long–term trends in country–level Reproduction Number and the Case Fatality Rate of COVID-19.
Our study also investigated the long–term statistical dependence of the COVID-19 Reproduction Number and the Case Fatality Rate on epidemiological, demographic, economic, immunization, and government policy factors in each country.
The findings of this study may have important implications for the health policy-makers worldwide.
The officially reported numbers of daily COVID-19 confirmed cases depend on the local testing policy and usually underestimate the true number of carriers in the population.
The officially reported numbers of daily COVID-19 deaths in some countries may include all deceased individuals who tested positive for COVID-19, disregarding their actual cause of death, and exclude victims who were not tested for COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval is needed for a retrospective study of publicly available country-level data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The results and the conclusions were updated with new data, available on Oct. 1. 2021.
Data Availability
All data used in this study is publicly available at https://ourworldindata.org/ and cited in the article.